Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.40−0.64 (-4.91%)
Close on Nov 18, 2026Market cap $460.59MP/E –Yield –
Crescent Biopharma shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Crescent Biopharma's shares outstanding was 65M at Mar 31, 2025. For fiscal 2024 it was 64M, up 1.8% from the year before. Over ten years it grew 13.3% a year on average. The highest annual figure on record is 64M in fiscal 2024.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 64M | +1.8% |
| FY2023 | Dec 31, 2023 | 63M | +20.6% |
| FY2022 | Dec 31, 2022 | 53M | +2.1% |
| FY2021 | Dec 31, 2021 | 51M | +12.5% |
| FY2020 | Dec 31, 2020 | 46M | +5.7% |
| FY2019 | Dec 31, 2019 | 43M | +5.4% |
| FY2018 | Dec 31, 2018 | 41M | +39.6% |
| FY2017 | Dec 31, 2017 | 29M | +38.3% |
| FY2016 | Dec 31, 2016 | 21M | +11.8% |
| FY2015 | Dec 31, 2015 | 19M | +3.0% |
| FY2014 | Dec 31, 2014 | 18M | +1442.6% |
| FY2013 | Dec 31, 2013 | 1M | -89.1% |
| FY2012 | Dec 31, 2012 | 11M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 65M | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | 64M | +0.1% |
| Q3 FY2024 | Sep 30, 2024 | 64M | +0.2% |
| Q2 FY2024 | Jun 30, 2024 | 64M | +0.3% |
| Q1 FY2024 | Mar 31, 2024 | 65M | +0.1% |
| Q4 FY2023 | Dec 31, 2023 | 64M | +21.6% |
| Q3 FY2023 | Sep 30, 2023 | 64M | +22.7% |
| Q2 FY2023 | Jun 30, 2023 | 64M | +22.6% |
| Q1 FY2023 | Mar 31, 2023 | 64M | +23.2% |
| Q4 FY2022 | Dec 31, 2022 | 53M | +1.8% |
| Q3 FY2022 | Sep 30, 2022 | 52M | +1.7% |
| Q2 FY2022 | Jun 30, 2022 | 52M | +1.7% |
| Q1 FY2022 | Mar 31, 2022 | 52M | +3.2% |
| Q4 FY2021 | Dec 31, 2021 | 52M | +8.4% |
| Q3 FY2021 | Sep 30, 2021 | 52M | +8.5% |
| Q2 FY2021 | Jun 30, 2021 | 52M | +17.7% |
| Q1 FY2021 | Mar 31, 2021 | 51M | +16.3% |
| Q4 FY2020 | Dec 31, 2020 | 48M | +10.7% |
| Q3 FY2020 | Sep 30, 2020 | 48M | +9.7% |
| Q2 FY2020 | Jun 30, 2020 | 44M | +1.4% |
| Q1 FY2020 | Mar 31, 2020 | 44M | +0.9% |
| Q4 FY2019 | Dec 31, 2019 | 43M | +0.5% |
| Q3 FY2019 | Sep 30, 2019 | 43M | +0.5% |
| Q2 FY2019 | Jun 30, 2019 | 43M | +0.9% |
| Q1 FY2019 | Mar 31, 2019 | 43M | +0.8% |
| Q4 FY2018 | Dec 31, 2018 | 43M | +26.4% |
| Q3 FY2018 | Sep 30, 2018 | 43M | +31.6% |
| Q2 FY2018 | Jun 30, 2018 | 43M | +57.2% |
| Q1 FY2018 | Mar 31, 2018 | 43M | +82.3% |
| Q4 FY2017 | Dec 31, 2017 | 34M | +47.7% |
| Q3 FY2017 | Sep 30, 2017 | 33M | +42.0% |
| Q2 FY2017 | Jun 30, 2017 | 27M | – |
| Q1 FY2017 | Mar 31, 2017 | 23M | – |
| Q4 FY2016 | Dec 31, 2016 | 23M | – |
| Q3 FY2016 | Sep 30, 2016 | 23M | – |
See a number that looks wrong?